Archives 2020 - Appili Therapeutics

NEWS

Archives 2020

December 22, 2020

Dr. Reddy’s Laboratories, Global Response Aid, and Appili Therapeutics Announce the Filing of an Application for REEQONUS™ (Favipiravir) Tablets for the Treatment of COVID-19 Under Health Canada’s Interim Order

December 2, 2020

First Patient Dosed in Appili Therapeutics’ Phase 3 Clinical Trial of Avigan® Tablets (Favipiravir) for the Treatment of COVID-19 in the United States

November 24, 2020

Health Canada Clears Appili Therapeutics for New Phase 3 Clinical Trial to Evaluate Avigan Tablets (Favipiravir) in the Prevention of COVID-19 in Exposed Individuals in the Community

November 13, 2020

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021

October 30, 2020

Appili Therapeutics Joins Dr. Reddy’s, Global Response Aid, and FUJIFILM in Advancing Avigan® Tablets for the Potential Treatment of COVID-19

October 29, 2020

Appili Therapeutics Appoints Drug Development Executive Don Cilla to the Newly Created Position of Chief Development Officer

October 27, 2020

Appili Therapeutics to Present at TSX Life Sciences Investor Day

October 27, 2020

Appili Therapeutics Announces Additional Funding for Its ATI-1701 Biodefense Program

October 20, 2020

First Participants Dosed in Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir for COVID-19 Outbreak Control in Canadian Long-Term Care Homes

September 14, 2020

Appili Therapeutics to Commence Trading on Main Board of the TSX Exchange

September 11, 2020

Appili Submits Protocol for a Phase 3 Study Evaluating Favipiravir for the Treatment of Patients with COVID-19 Infections to the US FDA

September 10, 2020

Appili Therapeutics to Participate in Upcoming Investor Conferences for H.C. Wainwright & Co. and Maxim Group LLC

August 14, 2020

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2021

August 13, 2020

Appili Therapeutics Announces Voting Results of Annual and Special Meeting of Shareholders

August 11, 2020

Appili Therapeutics Receives Eligibility for DTC Trading in the U.S

August 10, 2020

FDA Clears Appili Therapeutics to Expand its Phase 2 Clinical Trial of Favipiravir for the Potential Prevention of COVID-19 at U.S. Long-Term Care Facilities

July 30, 2020

Appili Prepares Canadian Long-Term Care Facilities to Enroll Participants in a Clinical Trial Evaluating Favipiravir as an Outbreak Control Agent Against COVID-19

June 24, 2020

Appili Therapeutics Announces FY 2020 Annual and Financial Results

June 15, 2020

Appili Therapeutics Commences Trading on the OTCQX Marketplace

June 10, 2020

Appili Therapeutics Announces Closing of Public Offering of $15,525,000 and Concurrent Private Placement of $1,440,000

June 5, 2020

Appili Therapeutics Announces Filing of Prospectus Supplement and Proposed Concurrent Private Placement

June 4, 2020

Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering in June 2020

June 3, 2020

Appili Therapeutics Announces Overnight Marketed Equity Offering

May 21, 2020

Health Canada Clears Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COVID-19 Outbreaks

May 11, 2020

Appili Therapeutics Submits CTA with Health Canada to Sponsor Prophylactic Phase 2 Clinical Trial Evaluating FUJIFILM Toyama Chemical’s Favipiravir as a Preventative Measure Against COVID-19 in Canadian Long-Term Care Facilities

May 4, 2020

Appili Therapeutics to Present at Maxim Group’s Infectious Disease Virtual Conference

April 21, 2020

Appili Therapeutics Names Infectious Disease Specialist Yoav Golan, MD, as its Chief Medical Officer

February 27, 2020

Appili Therapeutics Reports Financial and Operational Results for Third Quarter Fiscal Year 2020 Copy

February 20, 2020

Appili Therapeutics Announces Closing of Public Offering of $10,250,000

February 14, 2020

Appili Therapeutics Announces Upsizing of Previously Announced Equity Offering in February 2020

February 13, 2020

Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering

February 12, 2020

Appili Therapeutics Announces Overnight Marketed Equity Offering in February 2020

January 28, 2020

Researchers Present Positive Interim Data on Appili Therapeutics’ ATI-1701 Biodefense Program at 2020 ASM Biothreats

January 27, 2020

Appili Therapeutics Appoints Veteran Biotech Executive Dr. Juergen Froehlich to Its Board of Directors

January 7, 2020

Appili Celebrates a Notable 2019 and Looks Ahead to Significant Milestones in 2020